QUANTIFY RESEARCH is a global partner to the pharmaceutical industry in close partnership with academia, patients, public institutions & clinical experts.
Real-world evidence & analytics
Quantify is the leading provider of RWE generated from the world-renouned Nordic data. Through our local presence, expert staff, institutional know-how and more than 10 years’ hands-on experience with the Nordic data, we offer an unparalleled ability to advise and execute Nordic RWE studies with local and global applications. Quantify has a successful track record of advising clients on securing Nordic ethical approval, data access, and optimizing analysis for commercial or regulatory purposes. We also offer RWE services in the EU, UK, and US.
Modelling, Access & Strategy
Quantify is a global provider of health economic evidence and a specialist provider of Nordic market access services including economic models, reimbursement dossiers, and strategic advice. Our experience and expertise ensures an optimized, streamlined market access process across the Nordics. For non-technical stakeholders, Quantify also develops value tools and visualisation dashboards to enhance communication. Our expert staff include ex-payers, ex-pharma, modelling experts, and experienced project managers.
Evidence review & synthesis
Quantify has long standing experience reviewing, interpreting and communicating evidence as part of targeted or systematic literature reviews (SLR). Our team ensures these activities are done systematically, with a focus on usability, to support knowledge management and commercialization activities. QUANTIFY is experienced in summarizing the results of this work through meta-analyses and narrative reviews. Our team consists of 50% PhDs and integrated AI solutions to provide our clients with the very best services.
Press
Quantify help develop a treatment pathway model for low back pain in Sweden
The paper “A health economic lifetime treatment pathway model for low back pain in Sweden” has been published in the Journal of Medical Economics. Quantify’s Gylfi Olafsson, Emma Jonsson, and Fredrik Borgström are among the co-authors of the paper. Pubmed link
“The treatment gap after fracture in osteoporosis patients in Sweden” selected as a top 6 poster presentation at FFN 2017
The abstract “The treatment gap after fracture in osteoporosis patients in Sweden”, co-authored by Jonas Banefelt, Linda Karlsson, Gustaf Ortsäter, and Oskar Ström of Quantify, was selected as a top 6 poster presentation at the 6th Global Congress of The Fragility Fracture Network, held in Malmö August 24-26.
Linda Karlsson and Oskar Eklund publish paper on costs of autosomal dominant polycystic kidney disease in the Nordics
The paper “Real-world costs of autosomal dominant polycystic kidney disease in the Nordics” has been published in BMC Health Services Research. Linda Karlsson and Oskar Eklund of Quantify Research are among the co-authors of the paper. Pubmed link
Updated evaluation process for hospital pharmaceuticals in Denmark: Quantify interview with Amgros
Quantify has reviewed the new guidance on reimbursement applications for hospital pharmaceuticals in Denmark and has summarized the requirements and implications for the pharmaceutical industry. Economic analysis is now mandatory for submissions and along with medical effectiveness forms the basis for price negotiations with the authorities. The economic analysis is evaluated by Amgros, while the medical effectiveness is evaluated by the Medical Council (Medicinrådet).
To find out a bit […]